Skip to main content
. 2016 Jan 4;11(3):431–441. doi: 10.2215/CJN.06290615

Figure 2.

Figure 2.

Cumulative incidence of death is higher in patients with monoclonal gammopathies than in control patients. Cumulative incidence of death (considering transplantation and renal recovery as competing risks) in (A) patients with monoclonal gammopathies and control patients on chronic dialysis and (B) patients with AL amyloidosis (ALA), light–chain deposition disease (LCDD), or myeloma cast nephropathy (MCN) and control patients on chronic dialysis.